UK Healthtech Startup Nul Raises £888,000 Seed Round to Modernise Alcohol Reduction

Nul, a UK-based healthtech startup building a supported alcohol reduction platform which includes access to clinical care and prescription medication, has raised $1m in seed funding, led by dmg ventures, the venture arm of Daily Mail and General Trust, and BYVP, alongside a group of experienced angel investors.

Founded by Matus Maar, co-founder of Talis Capital and an early investor in companies including Darktrace, Nul is developing a telehealth platform that combines clinical care and prescription medication with digital pathways and behavioural support to help people reduce their alcohol consumption.

Alcohol use disorder and harmful drinking affect millions of people globally, yet treatment options have seen limited innovation for decades. Nul is targeting this gap with medication and therapy-supported reduction models designed for people who want to drink less, without the requirement for immediate or total abstinence.

The company’s core programme is built around naltrexone. Similar to GLP1, naltrexone plays on reward pathways and is used to reduce alcohol cravings. The programme is delivered through a fully remote, subscription-based service that includes virtual consultation, ongoing clinical support, and structured digital support based on The Sinclair Method, which is proven to have a 78% success rate*.

Nul launched a UK test phase in summer 2025 and has already onboarded more than 120 paying customers, reaching an annualised revenue run-rate of over £300,000 within its first few months, driven largely by organic demand and word-of-mouth.

The seed funding will support:

• A full UK commercial launch
• Expansion of the clinical and product teams
• Scaling customer acquisition
• Preparation for future international expansion, including the US

Alongside the announced seed round, Nul has just opened a crowdfunding campaign on Republic, allowing retail investors to participate in the round and support the company’s next phase of growth. This campaign is currently live and details about it can be found here: https://europe.republic.com/startups/31224/preview?token=6l5zs24nvdalh7po8apy1i9isqscuku

Matus Maar, founder and CEO of Nul said, “Alcohol reduction is one of the largest and least modernised areas in healthcare. Telehealth and online pharmacy platforms have transformed categories like weight loss and mental health, yet alcohol has been left behind despite the scale of the problem. Nul is about making evidence-based treatment accessible, discreet and compatible with real life.”

Rachel Muzyczka, Partner at dmg ventures said, “We are delighted to be partnering with Matus and the rest of the Nul team. Nul’s mission to empower individuals to take control of their relationship with alcohol is both timely and transformative. Their approach is not only innovative but deeply aligned with the growing demand for healthier lifestyles. We see tremendous potential in their approach and the market they’re serving

BYVP and dmg ventures participated in the round alongside a number of high-profile angel investors with backgrounds in technology, healthcare and consumer brands.

Nul plans to raise further capital in 2026 as it scales in the UK and enters new markets.

Further details about Nul can be found at: https://www.choosenul.com/ 

‍